Health Care·Biotechnology·$3.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.79 | N/A | +5.62% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.79 | N/A | +5.62% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management conveyed a cautious optimism about future prospects despite not providing specific guidance. They emphasized their commitment to innovation.
Management highlighted ongoing investments in R&D to drive future growth.
They acknowledged current market challenges but expressed confidence in long-term strategies.
Twist Bioscience's earnings report showed a mixed picture, with a narrower-than-expected loss per share but no revenue figures disclosed. The stock reacted positively, gaining 0.16%, likely due to the smaller-than-anticipated EPS loss and management's focus on future growth strategies. Investors may be encouraged by the company's commitment to R&D despite current market challenges.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
BANCO BILBAO VIZCAYA ADR
Apr 29, 2024